HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IDO-1 inhibitor LY3381916

Also Known As:

LY3381916

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bendell, Johanna: 1 article (01/2021)
2.	Benhadji, Karim A: 1 article (01/2021)
3.	Doman, Thompson N: 1 article (01/2021)
4.	Galvao, Violeta R: 1 article (01/2021)
5.	Gandhi, Leena: 1 article (01/2021)
6.	Geeganage, Sandaruwan: 1 article (01/2021)
7.	Jalal, Shadia: 1 article (01/2021)
8.	Kotecki, Nuria: 1 article (01/2021)
9.	O'Neil, Bert H: 1 article (01/2021)
10.	Prenen, Hans: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer." 01/01/2021 - "LY3381916, at the recommended phase II dose, 240 mg qd, in combination with PD-L1 inhibitor, produced maximal inhibition of indoleamine 2,3-dioxygenase 1 activity in plasma and tumor tissue, and led to an increase of CD8 T cells in tumor tissue. " 01/01/2021 - "LY3381916 is an orally available, highly selective, potent inhibitor of indoleamine 2,3-dioxygenase 1. This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combination with a programmed death-ligand 1 (PD-L1) inhibitor (LY3300054) in patients with advanced solid tumors. "
2.	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/01/2021 - "Dose-limiting toxicities occurred in 3 patients; 1 at LY3381916 240 mg twice daily (alanine aminotransferase/aspartate aminotransferase increase and systemic inflammatory response syndrome) and 2 at LY3381916 240 mg qd in combination with PD-L1 inhibitor (fatigue and immune-related hepatitis). "
3.	Hepatitis 01/01/2021 - "Dose-limiting toxicities occurred in 3 patients; 1 at LY3381916 240 mg twice daily (alanine aminotransferase/aspartate aminotransferase increase and systemic inflammatory response syndrome) and 2 at LY3381916 240 mg qd in combination with PD-L1 inhibitor (fatigue and immune-related hepatitis). "
4.	Fatigue 01/01/2021 - "Dose-limiting toxicities occurred in 3 patients; 1 at LY3381916 240 mg twice daily (alanine aminotransferase/aspartate aminotransferase increase and systemic inflammatory response syndrome) and 2 at LY3381916 240 mg qd in combination with PD-L1 inhibitor (fatigue and immune-related hepatitis). "

Related Drugs and Biologics

1.	B7-H1 Antigen
2.	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
3.	LY3300054
4.	Aspartate Aminotransferases (Aspartate Transaminase)
5.	Alanine Transaminase (SGPT)
6.	Immune Checkpoint Inhibitors